TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage immuno-oncology company, has released updated results from its Phase 1a clinical trial of TTX-MC138 in patients with relapsed or refractory, unresectable locally advanced or metastatic solid tumors. The data, as of September 1, showed that 10 of 14 efficacy-evaluable patients, or 71.4%, achieved stable disease as their best overall response. Six patients remained progression-free at three months, while three continued to be progression-free at six, nine, and twelve months. The disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1. A post-hoc Growth Modulation Index analysis found that six of 15 evaluable patients, or 40%, achieved a GMI greater than 1.3, indicating a progression-free interval at least 30% longer than with their immediately preceding therapy.
Safety data showed that a total of 98 doses had been administered as of September 1, with no dose-limiting toxicities reported and no treatment-emergent adverse events leading to treatment discontinuation, including at the highest evaluated dose of 4.8 mg/kg. Exploratory RNA-sequencing analysis identified treatment-associated immune effects that the company said support the observed clinical activity, although the small-sample biomarker findings require confirmation in larger studies. TransCode is evaluating dose-expansion strategies and plans to continue assessing safety, pharmacokinetics, pharmacodynamics, and antitumor activity.
The implications of this announcement are significant for the oncology community and investors. TTX-MC138 targets microRNA-10b, a well-documented biomarker of metastasis, and if further trials confirm its efficacy, it could offer a new therapeutic option for patients with advanced solid tumors who have limited treatment choices. The absence of dose-limiting toxicities is particularly encouraging, as it suggests a favorable safety profile that may allow for combination therapies or higher dosing in future studies.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For more details, the full press release is available at https://ibn.fm/mIBZR, and the latest news and updates relating to RNAZ can be found in the company's newsroom at https://ibn.fm/RNAZ.
The announcement was disseminated through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of a network of over 75 brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire and other services. For more information, visit BioMedWire. The full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
